NASDAQ: VERVVerve Therapeutics Inc Stock
$16.48-0.44 (-2.6%)
Updated Mar 17, 2023
VERV Price
$16.48
Fair Value Price
N/A
Market Cap
$1.02B
52 Week Low
$10.70
52 Week High
$43.00
P/E
-5.66x
P/B
1.85x
P/S
538.57x
PEG
N/A
Dividend Yield
N/A
Revenue
$1.94M
Earnings
-$157.39M
Gross Margin
100%
Operating Margin
-8,105.82%
Profit Margin
-8,108.6%
Debt to Equity
0.23
Operating Cash Flow
-$122M
Beta
2.02
Next Earnings
May 9, 2023
Ex-Dividend
N/A
Next Dividend
N/A
VERV Overview
Verve Therapeutics Incorporated developing a novel approach to the care of cardiovascular disease - transforming treatment from chronic management to single-course gene editing medicines. Verve's lead product candidate, VERVE-101, is designed to turn off the PCSK9 gene in the liver in order to disrupt blood PCSK9 protein production and thereby reduce blood LDL-C levels, with the goal of reducing a patient's risk for cardiovascular disease. Verve Therapeutics was incorporated in 2018 and is headquartered in Cambridge, MA.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VERV scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VERV is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
VERV is good value based on its book value relative to its share price (1.85x), compared to the US Biotechnology industry average (4.75x)
P/B vs Industry Valuation
VERV is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more VERV due diligence checks available for Premium users.
Be the first to know about important VERV news, forecast changes, insider trades & much more!
VERV News
Valuation
VERV fair value
Fair Value of VERV stock based on Discounted Cash Flow (DCF)
Price
$16.48
Fair Value
$26.85
Undervalued by
38.63%
VERV is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VERV price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-5.66x
Industry
16.18x
Market
21.81x
VERV price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.85x
Industry
4.75x
VERV is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VERV's financial health
Profit margin
Revenue
$1.0M
Net Income
-$41.1M
Profit Margin
-4,059.8%
VERV's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VERV's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$679.2M
Liabilities
$128.3M
Debt to equity
0.23
VERV's short-term assets ($563.16M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VERV's short-term assets ($563.16M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VERV's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$32.9M
Investing
-$168.3M
Financing
$39.6M
VERV's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VERV vs Biotech Stocks
Verve Therapeutics Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.